• 1
    Varney VA, Gaga M, Frew AJ, Aber VR, Kay AB, Durham SR. Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. Br Med J 1991;302: 265269.
  • 2
    Bousquet J, Lockey RF, Malling H-J. (eds). Allergen immunotherapy: therapeutic vaccines for allergic diseases (WHO position paper). Allergy 1998;53(Suppl. 44): 142.
  • 3
    Durham SR, Walker SM, Varga EM, Jacobson MR, O'Brien F, Noble W et al. Long-term clinical efficacy of grass pollen immunotherapy. N Eng J Med 1999;341: 468475.
  • 4
    Lichtenstein LM, Ishizaka K, Norman PS, Hill BM. IgE antibody measurements in ragweed hay fever, relationship to clinical severity and the results of immunotherapy. J Clin Invest 1973;52: 472482.
  • 5
    Creticos PS, Adkinson NF Jr, Kagey-Sobotka A, Proud D, Meier HL, Naclerio RM. Nasal challenge with ragweed pollen in hay fever patients. J Clin Invest 1985;76: 22472253.
  • 6
    Durham SR, Ying S, Varney VA, Jacobson MR, Sudderick RM, Mackay IS et al. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. J Allergy Clin Immunol 1996;97: 13561365.
  • 7
    Committee on Safety of Medicines. Desensitising vaccines. Brit Med J 1986;293: 948.
  • 8
    EAACI. EAACI Position paper. Consensus statement on the treatment of allergic rhinitis. Allergy 2000;55: 116134.
  • 9
    Andre C, Perrin-Fayolle M, Grosclaude M, Couturier P, Bassett D, Cornillon J et al. A double-blind placebo-controlled evaluation of sublingual immunotherapy with a standardised ragweed extract in patients with seasonal rhinitis, evidence for a dose–response relationship. Allergy 2002;57(S73): 31.
  • 10
    Ariano R, Spadolini I, Panzani RC. Efficacy of sublingual immunotherapy in Cupressaceae allergy using an extract of Cupressus arizonixa. A double-blind study. Allergol et immunopathol 2001;29: 238244.
  • 11
    Bahceciler NN, Isik U, Barlan IB, Basaran MM. Efficacy of sublingual immunotherapy in children with asthma and rhinitis: a double-blind, placebo-controlled study. Pediatr Pulmonol 2001;32: 4955.
  • 12
    Casanovas M, Guerra F, Moreno C, Miguel R, Maranon F, Daza JC. Double-blind, placebo-controlled clinical trial of preseasonal treatment with allergenic extracts of Olea europaea pollen administered sublingually. J Investig Allergol Clin Immunol 1994;4: 305314.
  • 13
    D'Ambrosio FP, Ricciardi L, Isola S, Savi E, Parmiani S, Puccinelli P et al. Rush sublingual immunotherapy in Parietaria allergic patients. Allergol Immunopathol (Madr) 1996;24: 146151.
  • 14
    Purello D'Ambrosio F. Sublingual immunotherapy: a double-blind, placebo-controlled trial with Parietaria judaica extract standardised in mass units in patients with rhinoconjunctivitis, asthma or both. Allergy 1999;54: 968973.
  • 15
    Feliziani V, Lattuada G, Parmiani S, Dall'Aglio PP. Safety and efficacy of sublingual rush immunotherapy with grass allergen extracts. A double blind study. Allergol Immunopathol (Madr) 1995;23: 224230.
  • 16
    Guez S, Vatrinet C, Fadel R, Andre C. House-dust-mite sublingual- swallow immunotherapy (SLIT) in perennial rhinitis: a double-blind, placebo-controlled study. Allergy 2000;55: 369375.
  • 17
    Hirsch T, Sahn M, Leupold W. Double-blind placebo-controlled study of sublingual immunotherapy with house dust mite extract ( in children. Pediatr Allergy Immunol 1997;8: 2127.
  • 18
    Hordijk GJ. Sublingual immunotherapy with a standardised grass pollen extract: a double-blind, placebo-controlled study. Allergol Immunopathol (Madr) 1998;26: 234240.
  • 19
    La Rosa M, Ranno C, Andre C, Carat F, Tosca MA, Canonica GW. Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardised Parietaria judaica extract in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 1999;104: 425432.
  • 20
    Lima M, Wilson DR, Roberts A, Walker SM, Durham SR. Grass Pollen Sublingual Immunotherapy (SLIT) for seasonal rhinoconjunctivitis: A randomised controlled trial. Clin Exp All 2002;32: 507514.
  • 21
    Mungan D, Misirligil Z, Gurbuz L. Comparison of the efficacy of subcutaneous and sublingual immunotherapy in mite-sensitive patients with rhinitis and asthma: a placebo controlled study. Ann Allergy Asthma Immunol 1999;82: 485490.
  • 22
    Nelson HS, Oppenheimer J, Vatsia GA, Buchmeier A. A double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized cat extract. J Allergy Clin Immunol 1993;92: 229236.
  • 23
    Passalacqua G, Albano M, Fregonese L, Riccio A, Mela GS, Canonica GW. Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis. Lancet 1998;351: 629632.
  • 24
    Passalacqua G, Albano M, Riccio A, Fregonese L, Puccinelli P, Parmiani S et al. Clinical and immunologic effects of a rush sublingual immunotherapy to Parietaria species: A double-blind placebo-controlled trial. J Allergy Clin Immunol 1999;104: 964968.
  • 25
    Pradalier A. Sublingual-swallow immunotherapy (SLIT) with a standardised five-grass pollen extract (drops and sublingual tablets) versus placebo in seasonal rhinitis. Allergy 1999;54: 819828.
  • 26
    Quirino T, Iemoli E, Siciliani E, Parmiani S, Milazzo F. Sublingual versus injective immunotherapy in grass pollen allergic patients: a double blind (double dummy) study. Clin Exp Allergy 1996;26: 12531261.
  • 27
    Tari MG, Mancino M, Monti G. Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite: a double-blind study. Allergol Immunopathol (Madr) 1990;18: 277284.
  • 28
    Troise C, Voltolini S, Canessa A, Pecora S, Negrini AC. Sublingual immunotherapy in Parietaria pollen-induced rhinitis: a double-blind study. J Investig Allergol Clin Immunol 1995;5: 2530.
  • 29
    Voltolini S, Modena P, Minale P, Bignardi D, Troise C, Puccinelli P et al. Sublingual immunotherapy in tree pollen allergy. Double-blind, placebo-controlled study with a biologically standardised extract of three pollens (alder, birch and hazel) administered by a rush schedule. Allergol Immunopathol (Madr) 2001;29: 103110.
  • 30
    Vourdas D, Syrigou E, Potamianou P, Carat F, Batard T, Andre C et al. Double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized olive pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive pollen sensitization. Allergy 1998;53: 662672.